Cargando…

Recent advances in the treatment of pancreatic cancer

Pancreatic ductal adenocarcinoma is one of the deadliest solid tumor malignancies and is projected to become a leading cause of cancer-related death in coming years. Improving quality of life and survival amongst these patients will require new ideas and novel therapies in a multidisciplinary approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Marc T, Cardin, Dana B, Berlin, Jordan D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043109/
https://www.ncbi.nlm.nih.gov/pubmed/32148767
http://dx.doi.org/10.12688/f1000research.21981.1
_version_ 1783501396362919936
author Roth, Marc T
Cardin, Dana B
Berlin, Jordan D
author_facet Roth, Marc T
Cardin, Dana B
Berlin, Jordan D
author_sort Roth, Marc T
collection PubMed
description Pancreatic ductal adenocarcinoma is one of the deadliest solid tumor malignancies and is projected to become a leading cause of cancer-related death in coming years. Improving quality of life and survival amongst these patients will require new ideas and novel therapies in a multidisciplinary approach. This review will cover the most recent advances in the comprehensive treatment of pancreatic cancer and place them within a historical context when necessary. Treatment of all disease stages will be discussed, but the focus is on systemic therapy as novel drugs and new treatment combinations enter the clinic. This will include more aggressive chemotherapy in earlier disease stages, approved uses for immunotherapy, and targetable mutations. In addition, negative trials of importance and controversial topics will be noted.
format Online
Article
Text
id pubmed-7043109
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-70431092020-03-05 Recent advances in the treatment of pancreatic cancer Roth, Marc T Cardin, Dana B Berlin, Jordan D F1000Res Review Pancreatic ductal adenocarcinoma is one of the deadliest solid tumor malignancies and is projected to become a leading cause of cancer-related death in coming years. Improving quality of life and survival amongst these patients will require new ideas and novel therapies in a multidisciplinary approach. This review will cover the most recent advances in the comprehensive treatment of pancreatic cancer and place them within a historical context when necessary. Treatment of all disease stages will be discussed, but the focus is on systemic therapy as novel drugs and new treatment combinations enter the clinic. This will include more aggressive chemotherapy in earlier disease stages, approved uses for immunotherapy, and targetable mutations. In addition, negative trials of importance and controversial topics will be noted. F1000 Research Limited 2020-02-21 /pmc/articles/PMC7043109/ /pubmed/32148767 http://dx.doi.org/10.12688/f1000research.21981.1 Text en Copyright: © 2020 Roth MT et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Roth, Marc T
Cardin, Dana B
Berlin, Jordan D
Recent advances in the treatment of pancreatic cancer
title Recent advances in the treatment of pancreatic cancer
title_full Recent advances in the treatment of pancreatic cancer
title_fullStr Recent advances in the treatment of pancreatic cancer
title_full_unstemmed Recent advances in the treatment of pancreatic cancer
title_short Recent advances in the treatment of pancreatic cancer
title_sort recent advances in the treatment of pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043109/
https://www.ncbi.nlm.nih.gov/pubmed/32148767
http://dx.doi.org/10.12688/f1000research.21981.1
work_keys_str_mv AT rothmarct recentadvancesinthetreatmentofpancreaticcancer
AT cardindanab recentadvancesinthetreatmentofpancreaticcancer
AT berlinjordand recentadvancesinthetreatmentofpancreaticcancer